- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04221282
ZEBinix® Retention Rate in Epilepsy in Elderly Patients (ZEBRE)
January 7, 2020 updated by: Centre Hospitalier Saint Joseph Saint Luc de Lyon
ZEBinix Retention Rate in Epilepsy in Elderly Patients
The incidence of provoked and unprovoked seizures is known to increase with advancing age.
Eslicarbazepine acetate (ESL) is one of the third generation of antiepileptic drugs (AEDs) that have been developed in the last ten years with a favorable safety profile.
ESL is approved in Europe and the USA as adjunctive or monotherapy in adults with partial-onset seizures.
Nevertheless, retrospective data in monotherapy condition in the elderly epileptic population are sparse.
The aim of the ZEBRE study is to evaluate the efficacy and the safety of ESL in elderly epileptic patients (> 65 years).
The completion of this study will provide crucial information on the most appropriate ESL treatment for elderly patients suffering from partial seizures.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The ZEBRE (ZEBinix® Retention rate in epilepsy in Elderly patients) study is a prospective, multicenter, descriptive study.
ESL will be prescribed according to the usual care.
Posology and method of administration of ESL are defined by the summary of product characteristics.
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Adrien DIDELOT, MD, PhD
- Phone Number: 0033478616172
- Email: adidelot@ch-stjoseph-stluc-lyon.fr
Study Locations
-
-
-
Lyon, France, 69007
- Recruiting
- Centre Hospitalier St Joseph St Luc
-
Contact:
- Adrien DIDELOT, MD, PhD
- Phone Number: 0033478616172
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Elderly patients ≥ 65 years that undergo at least one seizure in the last three months and with no history of ESL tratment or history of epilepsy status will be screened.
ESL will be initiated by the investigator in patients with refractory partial seizures with or without generalized seizures or with PGTC seizures as a first line monotherapy or adjunctive therapy.
In case of inefficacy or toxicity the dose of ESL will be gradually titrated up to 1 600 mg or titrated down to 600 mg, respectively.
Description
Inclusion Criteria:
- Age ≥ 65 years
- Ability of patient/legal representative to understand the study and to give his/her non-opposition (at the investigator's discretion)
- Epilepsy with refractory partial-onset seizures with or without secondary generalization confirmed or with primary generalized tonic-clonic (PGTC) seizures
- At least one seizure in the last three months
- Treatment for partial-onset seizures with ESL as a first line monotherapy or with an adjunctive therapy
Exclusion Criteria:
- History of ESL treatment
- History of status epilepticus, seizures occurring in cluster, pseudo-seizures
- History of severe hepatic impairment (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2 times ULN, gamma-glutamyltranspeptidase (GGT) > 5 times ULN)
- History of severe renal impairment (clearance CLCR <30ml/min)
- History of hypersensitivity to other carboxamide derivatives (e.g. carbamazepine, oxcarbazepine)
- History of severe hyponatremia (< 120 mmol/L)
- Second or third degree atrioventricular block
- More than one other antiepileptic drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Epileptic elderly patients
Elderly patients with partial-onset seizures
|
ESL will be initiated by the investigator in patients as a first line monotherapy or adjunctive therapy.
ESL will be prescribed according to the usual care.
Posology and method of administration of ESL are defined by the summary of product characteristics.
Then, data on the efficacy of ESL will be collected.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retention rate of ESL treatment as assessed by the number of patients that are still included in the study.
Time Frame: at the end of the study treatment, at 6 months
|
The retention rate is representative of the effect of ESL since ESL will be pursued only if ESL has a sufficient efficacy without adverse effect.
To evaluate the effect of ESL in elderly patients with partial-onset seizures, the retention rate will be measured after 6 months of treatment with ESL.
|
at the end of the study treatment, at 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life of patients as assessed by QOLIE-10 questionnaire
Time Frame: at each visits required by the study (baseline, 3 months and 6 months)
|
QOLIE-10 (quality of life in epilepsy) is a quality of life questionnaire for adults with epilepsy.
There are 10 questions about health and daily activities.
All positive responses are lower numbers and all negative responses are higher numbers.
|
at each visits required by the study (baseline, 3 months and 6 months)
|
Quality of life of patients as assessed by QoL-AD questionnaire
Time Frame: at each visits required by the study (baseline, 3 months and 6 months)
|
Some patients with epilepsy also have cognitive decline.
QOL-AD (quality of life in Alzheimer'disease) measure quality of life in people with severe cognitive decline.
A total score of 13-52, with higher scores indicating better QoL.
|
at each visits required by the study (baseline, 3 months and 6 months)
|
Quality of life of patients as assessed by NDDIE questionnaire
Time Frame: at each visits required by the study (baseline, 3 months and 6 months)
|
NDDI-E (neurological disorder depression inventory for epilepsy) is used for detecting major depressive disorder; a total score above 15 should raise the suspicion of a major depressive episode.
|
at each visits required by the study (baseline, 3 months and 6 months)
|
Incidence of treatment- adverse events as assessed by adverse events reports
Time Frame: through study completion, an average of 6 months
|
Number of patients with treatment-related adverse events will be reported to the pharmacovigilance department.
Number of participants with abnormal laboratory values and/or adverse events that are related to treatment will be assessed.
|
through study completion, an average of 6 months
|
Incidence of seizures as assessed by the occurrence of seizures
Time Frame: at each visits required by the study (baseline, 3 months and 6 months)
|
The number and the type of seizures or the number of seizure free in elderly patients will be reported
|
at each visits required by the study (baseline, 3 months and 6 months)
|
Observance of the treatment as recorded by the control of the drug administration
Time Frame: through study completion, an average of 6 months
|
The treatment delivery by the pharmacy be performed to assess the compliance of the treatment.
|
through study completion, an average of 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Adrien DIDELOT, MD, PhD, Centre Hospitalier saint Joseph St Luc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2019
Primary Completion (Anticipated)
September 30, 2020
Study Completion (Anticipated)
September 30, 2020
Study Registration Dates
First Submitted
November 5, 2019
First Submitted That Met QC Criteria
January 7, 2020
First Posted (Actual)
January 9, 2020
Study Record Updates
Last Update Posted (Actual)
January 9, 2020
Last Update Submitted That Met QC Criteria
January 7, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZEBRE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Zebinix
-
Whanin Pharmaceutical CompanyCompletedPartial-onset Seizures With or Without Secondary GeneralisationKorea, Republic of
-
Bial - Portela C S.A.CompletedPainful Diabetic Neuropathy
-
Bial - Portela C S.A.CompletedEpilepsySpain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
-
Bial - Portela C S.A.CompletedEfficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial SeizuresRefractory Partial EpilepsyPortugal
-
Bial - Portela C S.A.Completed
-
Bial - Portela C S.A.Completed
-
Bial - Portela C S.A.CompletedNeuropathic PainPortugal
-
Bial - Portela C S.A.Completed
-
Bial - Portela C S.A.Terminated
-
Bial - Portela C S.A.Completed